{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T15:22:08Z","timestamp":1772810528626,"version":"3.50.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"SJJ Solutions"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00417-025-07005-2","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T08:13:19Z","timestamp":1763367199000},"page":"753-762","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Intravitreal injection delivered volume under different environmental and training conditions"],"prefix":"10.1007","volume":"264","author":[{"given":"Mateus Lins","family":"dos Santos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucas Andrade","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre Lima","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydianne Lumack Monte","family":"Agra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge Artur Pe\u00e7anha Miranda","family":"Coelho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5765-2008","authenticated-orcid":false,"given":"Gustavo Barreto","family":"Melo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"4","key":"7005_CR1","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000486145","volume":"239","author":"A Grzybowski","year":"2018","unstructured":"Grzybowski A, Told R, Sacu S, Bandello F, Moisseiev E, Loewenstein A, Schmidt-Erfurth U, Euretina B (2018) 2018 update on intravitreal injections: euretina expert consensus recommendations. Ophthalmologica 239(4):181\u2013193. https:\/\/doi.org\/10.1159\/000486145","journal-title":"Ophthalmologica"},{"issue":"7","key":"7005_CR2","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41433-021-01646-3","volume":"36","author":"R Chopra","year":"2022","unstructured":"Chopra R, Preston GC, Keenan TDL, Mulholland P, Patel PJ, Balaskas K, Hamilton RD, Keane PA (2022) Intravitreal injections: past trends and future projections within a UK tertiary hospital. Eye (Lond) 36(7):1373\u20131378. https:\/\/doi.org\/10.1038\/s41433-021-01646-3","journal-title":"Eye (Lond)"},{"issue":"1","key":"7005_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13010108","volume":"13","author":"HM Kim","year":"2021","unstructured":"Kim HM, Woo SJ (2021) Ocular drug delivery to the retina: current innovations and future perspectives. Pharmaceutics 13(1):108. https:\/\/doi.org\/10.3390\/pharmaceutics13010108","journal-title":"Pharmaceutics"},{"issue":"1","key":"7005_CR4","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/aos.14876","volume":"100","author":"A Fern\u00e1ndez-Vega Gonz\u00e1lez","year":"2022","unstructured":"Fern\u00e1ndez-Vega Gonz\u00e1lez A, Muni RH (2022) The history of pneumatic retinopexy: have we come full circle? Acta Ophthalmol 100(1):118\u2013120. https:\/\/doi.org\/10.1111\/aos.14876","journal-title":"Acta Ophthalmol"},{"issue":"3","key":"7005_CR5","first-page":"1093","volume":"17","author":"M Afarid","year":"2018","unstructured":"Afarid M, Sadegi Sarvestani A, Rahat F, Azimi A (2018) Intravitreal injection of bevacizumab: review of our previous experience. Iran J Pharm Res 17(3):1093\u20131098","journal-title":"Iran J Pharm Res"},{"issue":"5","key":"7005_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s40266-014-0176-2","volume":"31","author":"LP Yang","year":"2014","unstructured":"Yang LP, McKeage K (2014) Intravitreal aflibercept (Eylea(\u00ae)): a review of its use in patients with macular oedema secondary to central retinal vein occlusion. Drugs Aging 31(5):395\u2013404. https:\/\/doi.org\/10.1007\/s40266-014-0176-2","journal-title":"Drugs Aging"},{"issue":"6","key":"7005_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12325-017-0548-1","volume":"34","author":"N Dervenis","year":"2017","unstructured":"Dervenis N, Mikropoulou AM, Tranos P, Dervenis P (2017) Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges. Adv Ther 34(6):1270\u20131282. https:\/\/doi.org\/10.1007\/s12325-017-0548-1","journal-title":"Adv Ther"},{"issue":"12","key":"7005_CR8","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1007\/s12325-023-02675-y","volume":"40","author":"C Watkins","year":"2023","unstructured":"Watkins C, Paulo T, B\u00fchrer C, Holekamp NM, Bagijn M (2023) Comparative efficacy, durability and safety of faricimab in the treatment of diabetic macular edema: a systematic literature review and network meta-analysis. Adv Ther 40(12):5204\u20135221. https:\/\/doi.org\/10.1007\/s12325-023-02675-y","journal-title":"Adv Ther"},{"key":"7005_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/164_2016_78","volume":"242","author":"YM Paulus","year":"2017","unstructured":"Paulus YM, Sodhi A (2017) Anti-angiogenic therapy for retinal disease. Handb Exp Pharmacol 242:271\u2013307. https:\/\/doi.org\/10.1007\/164_2016_78","journal-title":"Handb Exp Pharmacol"},{"issue":"2","key":"7005_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007920.pub3","volume":"2","author":"A Simha","year":"2020","unstructured":"Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB (2020) Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database Syst Rev 2(2):CD007920. https:\/\/doi.org\/10.1002\/14651858.CD007920.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"7005_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-019-0189-4","volume":"10","author":"SS Saincher","year":"2020","unstructured":"Saincher SS, Gottlieb C (2020) Ozurdex (dexamethasone intravitreal implant) for the treatment of intermediate, posterior, and panuveitis: a systematic review of the current evidence. J Ophthalmic Inflamm Infect 10(1):1. https:\/\/doi.org\/10.1186\/s12348-019-0189-4","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"12","key":"7005_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122580","volume":"10","author":"OA Halawa","year":"2021","unstructured":"Halawa OA, Lin JB, Miller JW, Vavvas DG (2021) A review of completed and ongoing complement inhibitor trials for geographic atrophy secondary to age-related macular degeneration. J Clin Med 10(12):2580. https:\/\/doi.org\/10.3390\/jcm10122580","journal-title":"J Clin Med"},{"issue":"1","key":"7005_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12348-015-0069-5","volume":"6","author":"MM Sachdeva","year":"2016","unstructured":"Sachdeva MM, Moshiri A, Leder HA, Scott AW (2016) Endophthalmitis following intravitreal injection of anti-VEGF agents: long-term outcomes and the identification of unusual micro-organisms. J Ophthalmic Inflamm Infect 6(1):2. https:\/\/doi.org\/10.1186\/s12348-015-0069-5","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"7005_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030876","volume":"11","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Shimada H, Mori R, Kitagawa Y, Onoe H, Tamura K, Nakashizuka H (2022) Safety measures for maintaining low endophthalmitis rate after intravitreal anti-vascular endothelial growth factor injection before and during the COVID-19 pandemic. J Clin Med 11(3):876. https:\/\/doi.org\/10.3390\/jcm11030876","journal-title":"J Clin Med"},{"issue":"3","key":"7005_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1590\/s0004-27492013000300010","volume":"76","author":"LG Freitas","year":"2013","unstructured":"Freitas LG, Isaac DL, Tannure WT, Gabriel LA, Reis RG, Rassi AR, Freitas CA, \u00c1vila MP (2013) Intravitreal bevacizumab combined with Infliximab in the treatment of choroidal neovascularization secondary to age-related macular degeneration: case report series. Arq Bras Oftalmol 76(3):180\u2013184. https:\/\/doi.org\/10.1590\/s0004-27492013000300010","journal-title":"Arq Bras Oftalmol"},{"issue":"2","key":"7005_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000521576","volume":"65","author":"Z Zhong","year":"2022","unstructured":"Zhong Z, He Z, Yu X, Zhang Y (2022) Intravitreal injection is associated with increased posterior capsule rupture risk during cataract surgery: a meta-analysis. Ophthalmic Res 65(2):152\u2013161. https:\/\/doi.org\/10.1159\/000521576","journal-title":"Ophthalmic Res"},{"issue":"10","key":"7005_CR17","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.ophtha.2019.04.037","volume":"126","author":"PP Storey","year":"2019","unstructured":"Storey PP, Pancholy M, Wibbelsman TD, Obeid A, Su D, Borkar D, Garg S, Gupta O (2019) Rhegmatogenous retinal detachment after intravitreal injection of anti-vascular endothelial growth factor. Ophthalmology 126(10):1424\u20131431. https:\/\/doi.org\/10.1016\/j.ophtha.2019.04.037","journal-title":"Ophthalmology"},{"issue":"1","key":"7005_CR18","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1038\/s41598-018-28938-1","volume":"8","author":"YI Shin","year":"2018","unstructured":"Shin YI, Sung JY, Sagong M, Lee YH, Jo YJ, Kim JY (2018) Risk factors for breakthrough vitreous hemorrhage after intravitreal anti-VEGF injection in age-related macular degeneration with submacular hemorrhage. Sci Rep 8(1):10560. https:\/\/doi.org\/10.1038\/s41598-018-28938-1","journal-title":"Sci Rep"},{"issue":"4","key":"7005_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ophtha.2018.11.019","volume":"126","author":"A Hoguet","year":"2019","unstructured":"Hoguet A, Chen PP, Junk AK, Mruthyunjaya P, Nouri-Mahdavi K, Radhakrishnan S, Takusagawa HL, Chen TC (2019) The effect of Anti-Vascular endothelial growth factor agents on intraocular pressure and glaucoma: A report by the American academy of ophthalmology. Ophthalmology 126(4):611\u2013622. https:\/\/doi.org\/10.1016\/j.ophtha.2018.11.019","journal-title":"Ophthalmology"},{"issue":"10","key":"7005_CR20","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.oret.2023.06.003","volume":"7","author":"LLM Agra","year":"2023","unstructured":"Agra LLM, Sverstad A, Chagas TA, Ara\u00fajo RH, Oliveira LG, Kristianslund O, Petrovski G, Maia M, Moe MC, J\u00f8rstad \u00d8K, Melo GB (2023) Accuracy, precision, and residual volume of commonly used syringes for intravitreal injections and the impact on intraocular pressure. Ophthalmol Retina 7(10):892\u2013900. https:\/\/doi.org\/10.1016\/j.oret.2023.06.003","journal-title":"Ophthalmol Retina"},{"issue":"1","key":"7005_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00517-1","volume":"9","author":"CH Meyer","year":"2023","unstructured":"Meyer CH, Melo GB, Khanani AM (2023) Can intravitreal injections with higher volume cause higher intraocular eye pressure? Considerations for anti-complement injections in normal and glaucomatous eyes. Int J Retina Vitreous 9(1):80. https:\/\/doi.org\/10.1186\/s40942-023-00517-1","journal-title":"Int J Retina Vitreous"},{"issue":"4","key":"7005_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jamaophthalmol.2017.0059","volume":"135","author":"BD Eadie","year":"2017","unstructured":"Eadie BD, Etminan M, Carleton BC, Maberley DA, Mikelberg FS (2017) Association of repeated intravitreous bevacizumab injections with risk for glaucoma surgery. JAMA Ophthalmol 135(4):363\u2013368. https:\/\/doi.org\/10.1001\/jamaophthalmol.2017.0059","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"7005_CR23","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jcjo.2021.06.025","volume":"58","author":"SS Bae","year":"2023","unstructured":"Bae SS, Koenigstein D, Weaver T, Merkur A, Albiani D, Pakzad-Vaezi K, Kirker A (2023) Incidence of ocular hypertension after anti-VEGF injections: examining the effect of drug filtration and silicone-free syringes. Can J Ophthalmol 58(1):66\u201372. https:\/\/doi.org\/10.1016\/j.jcjo.2021.06.025","journal-title":"Can J Ophthalmol"},{"key":"7005_CR24","doi-asserted-by":"publisher","unstructured":"Fugara NA, Shawareb ZA, Rakkad NK, Barhoum ML, Shawareb BA, Al-Madani MM, Al-Madani MV (2022) The Risk of Non-arteritic Ischemic Optic Neuropathy Post-intravitreal Bevacizumab Injection. Cureus. 2022;14(10):e30185. https:\/\/doi.org\/10.7759\/cureus.30185","DOI":"10.7759\/cureus.30185"},{"issue":"7","key":"7005_CR25","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond) 27(7):787\u2013794. https:\/\/doi.org\/10.1038\/eye.2013.107","journal-title":"Eye (Lond)"},{"issue":"7","key":"7005_CR26","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1600-0420.2007.00939.x","volume":"85","author":"K Kotliar","year":"2007","unstructured":"Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I (2007) Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 85(7):777\u2013781. https:\/\/doi.org\/10.1111\/j.1600-0420.2007.00939.x","journal-title":"Acta Ophthalmol Scand"},{"key":"7005_CR27","doi-asserted-by":"publisher","first-page":"897","DOI":"10.2147\/OPTH.S207978","volume":"14","author":"M Schargus","year":"2020","unstructured":"Schargus M, Frings A (2020) Issues with intravitreal administration of anti-VEGF drugs. Clin Ophthalmol 14:897\u2013904. https:\/\/doi.org\/10.2147\/OPTH.S207978","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"7005_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1089\/jop.2014.0062","volume":"31","author":"AM Ricca","year":"2015","unstructured":"Ricca AM, Morshedi RG, Wirostko BM (2015) High intraocular pressure following anti-vascular endothelial growth factor therapy: proposed pathophysiology due to altered nitric oxide metabolism. J Ocul Pharmacol Ther 31(1):2\u201310. https:\/\/doi.org\/10.1089\/jop.2014.0062","journal-title":"J Ocul Pharmacol Ther"},{"key":"7005_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.exer.2016.02.006","volume":"145","author":"O Gal-Or","year":"2016","unstructured":"Gal-Or O, Dotan A, Dachbash M, Tal K, Nisgav Y, Weinberger D, Ehrlich R, Livnat T (2016) Bevacizumab clearance through the iridocorneal angle following intravitreal injection in a rat model. Exp Eye Res 145:412\u2013416. https:\/\/doi.org\/10.1016\/j.exer.2016.02.006","journal-title":"Exp Eye Res"},{"issue":"1","key":"7005_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-021-00322-8","volume":"7","author":"Y Keshet","year":"2021","unstructured":"Keshet Y, Gal-Or O, Schaap Fogler M, Mimouni K, Ben Ishai M, Weinberger D, Dotan A (2021) Aflibercept clearance through the drainage system in a rat model. Int J Retina Vitreous 7(1):53. https:\/\/doi.org\/10.1186\/s40942-021-00322-8","journal-title":"Int J Retina Vitreous"},{"issue":"2","key":"7005_CR31","doi-asserted-by":"publisher","first-page":"236","DOI":"10.4103\/ijo.IJO_1028_20","volume":"69","author":"A Sudhalkar","year":"2021","unstructured":"Sudhalkar A, Bilgic A, Vasavada S, Kodjikian L, Mathis T, de Ribot FM, Papakostas T, Vasavada V, Vasavada V, Srivastava S, Bhojwani D, Ghia P, Sudhalkar A (2021) Current intravitreal therapy and ocular hypertension: a review. Indian J Ophthalmol 69(2):236\u2013243. https:\/\/doi.org\/10.4103\/ijo.IJO_1028_20","journal-title":"Indian J Ophthalmol"},{"issue":"3","key":"7005_CR32","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-021-01949-4","volume":"22","author":"AC Parenky","year":"2021","unstructured":"Parenky AC, Wadhwa S, Chen HH, Bhalla AS, Graham KS, Shameem M (2021) Container closure and delivery considerations for intravitreal drug administration. AAPS PharmSciTech 22(3):100. https:\/\/doi.org\/10.1208\/s12249-021-01949-4","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"7005_CR33","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1080\/02713683.2016.1276195","volume":"42","author":"E Moisseiev","year":"2017","unstructured":"Moisseiev E, Rudell J, Tieu EV, Yiu G (2017) Effect of syringe design on the accuracy and precision of intravitreal injections of anti-VEGF agents. Curr Eye Res 42(7):1059\u20131063. https:\/\/doi.org\/10.1080\/02713683.2016.1276195","journal-title":"Curr Eye Res"},{"issue":"4","key":"7005_CR34","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3928\/23258160-20130601-02","volume":"44","author":"KM Sampat","year":"2013","unstructured":"Sampat KM, Wolfe JD, Shah MK, Garg SJ (2013) Accuracy and reproducibility of seven brands of small-volume syringes used for intraocular drug delivery. Ophthalmic Surg Lasers Imaging Retina 44(4):385\u2013389. https:\/\/doi.org\/10.3928\/23258160-20130601-02","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"issue":"4","key":"7005_CR35","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1055\/s-0029-1245183","volume":"227","author":"H Gerding","year":"2010","unstructured":"Gerding H, Timmermann M (2010) Accuracy and precision of intravitreally injected Ranibizumab doses: an experimental study. Klin Monbl Augenheilkd 227(4):269\u2013272. https:\/\/doi.org\/10.1055\/s-0029-1245183","journal-title":"Klin Monbl Augenheilkd"},{"issue":"2","key":"7005_CR36","doi-asserted-by":"publisher","first-page":"e165","DOI":"10.1111\/j.1755-3768.2010.02072.x","volume":"90","author":"CH Meyer","year":"2012","unstructured":"Meyer CH, Liu Z, Brinkmann C, Rodrigues EB, Helb HM (2012) Accuracy, precision and repeatability in preparing the intravitreal dose with a 1.0-cc syringe. Acta Ophthalmol 90(2):e165\u2013e166. https:\/\/doi.org\/10.1111\/j.1755-3768.2010.02072.x","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"7005_CR37","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1097\/IAE.0000000000002170","volume":"39","author":"I Loewenstein","year":"2019","unstructured":"Loewenstein I, Goldstein M, Moisseiev J, Moisseiev E (2019) Accuracy and precision of intravitreal injections of anti-vascular endothelial growth factor agents in real life: what is actually in the syringe? Retina 39(7):1385\u20131391. https:\/\/doi.org\/10.1097\/IAE.0000000000002170","journal-title":"Retina"},{"key":"7005_CR38","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2147\/OPTH.S169044","volume":"13","author":"TM Sassalos","year":"2019","unstructured":"Sassalos TM, Paulus YM (2019) Prefilled syringes for intravitreal drug delivery. Clin Ophthalmol 13:701\u2013706. https:\/\/doi.org\/10.2147\/OPTH.S169044","journal-title":"Clin Ophthalmol"},{"issue":"10","key":"7005_CR39","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02880-2","volume":"37","author":"C Weinmann","year":"2020","unstructured":"Weinmann C, Sediq AS, Vogt M, Mahler HC, Joerg S, Rodriguez S, Mathaes R, Jere D (2020) Role of formulation parameters on intravitreal dosing accuracy using 1 mL hypodermic syringes. Pharm Res 37(10):190. https:\/\/doi.org\/10.1007\/s11095-020-02880-2","journal-title":"Pharm Res"},{"issue":"12","key":"7005_CR40","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1007\/s00417-021-05302-0","volume":"259","author":"M Krauthammer","year":"2021","unstructured":"Krauthammer M, Trabelsi E, Moisseiev E (2021) Intravitreal air bubbles following intravitreal injections: a comprehensive analysis. Graefes Arch Clin Exp Ophthalmol 259(12):3697\u20133702. https:\/\/doi.org\/10.1007\/s00417-021-05302-0","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"2","key":"7005_CR41","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1177\/1120672120977820","volume":"31","author":"E Havuz","year":"2021","unstructured":"Havuz E, G\u00fcd\u00fcl Havuz S, Gokmen O (2021) The influence of dead spaces and the designs of injectors on the amount of drug dose in intra-vitreal injection. Eur J Ophthalmol 31(2):592\u2013599. https:\/\/doi.org\/10.1177\/1120672120977820","journal-title":"Eur J Ophthalmol"},{"issue":"2","key":"7005_CR42","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41433-023-02670-1","volume":"38","author":"GB Melo","year":"2024","unstructured":"Melo GB, Santos LA, Agra LLDM, Meyer C, Moe MC, J\u00f8rstad \u00d8K (2024) Accuracy and residual volume of intravitreal injection syringes in administration of very small volumes. Eye (Lond) 38(2):395\u2013396. https:\/\/doi.org\/10.1038\/s41433-023-02670-1","journal-title":"Eye (Lond)"},{"issue":"3","key":"7005_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/IAE.0000000000003693","volume":"43","author":"M Krauthammer","year":"2023","unstructured":"Krauthammer M, Harel G, Moisseiev E (2023) Syringe design and filling technique affect accuracy of anti-vascular endothelial growth factor intravitreal injections. Retina 43(3):514\u2013519. https:\/\/doi.org\/10.1097\/IAE.0000000000003693","journal-title":"Retina"},{"key":"7005_CR44","doi-asserted-by":"publisher","DOI":"10.3389\/fopht.2022.882013","volume":"2","author":"TT Gj\u00f8lberg","year":"2022","unstructured":"Gj\u00f8lberg TT, Lode HE, Melo GB, Mester S, Probst C, Sivertsen MS, J\u00f8rstad \u00d8K, Andersen JT, Moe MC (2022) A silicone oil-free syringe tailored for intravitreal injection of biologics. Front Ophthalmol 2:882013. https:\/\/doi.org\/10.3389\/fopht.2022.882013","journal-title":"Front Ophthalmol"},{"issue":"1","key":"7005_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-23039-6","volume":"12","author":"VLS Dingerkus","year":"2022","unstructured":"Dingerkus VLS, Somfai GM, Kinzl S, Org\u00fcl SI, Becker MD, Heussen FM (2022) Incidence of severe rise in intraocular pressure after intravitreous injection of Aflibercept with prefilled syringes. Sci Rep 12(1):18136. https:\/\/doi.org\/10.1038\/s41598-022-23039-6","journal-title":"Sci Rep"},{"issue":"4","key":"7005_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2022.100202","volume":"2","author":"JJ Raevis","year":"2022","unstructured":"Raevis JJ, Lemire CA, Ramsey DJ, Riccobono J, Gonzalez E (2022) Deformation of aflibercept and ranibizumab syringes causes variation in intravitreal injection volume and risks retinal tear formation. Ophthalmol Sci 2(4):100202. https:\/\/doi.org\/10.1016\/j.xops.2022.100202","journal-title":"Ophthalmol Sci"},{"issue":"1","key":"7005_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-022-00375-3","volume":"8","author":"JM Guest","year":"2022","unstructured":"Guest JM, Malbin B, Abrams G, Parendo A, Das S, Okeagu C, Ross BX, Kumar A, Lin X (2022) Accuracy of intravitreal injection volume for Aflibercept pre-filled syringe and BD Luer-Lok one-milliliter syringe. Int J Retina Vitreous 8(1):27. https:\/\/doi.org\/10.1186\/s40942-022-00375-3","journal-title":"Int J Retina Vitreous"},{"issue":"1","key":"7005_CR48","doi-asserted-by":"publisher","first-page":"e43","DOI":"10.1055\/s-0039-1688912","volume":"11","author":"JJ Liechty","year":"2019","unstructured":"Liechty JJ, Wilkinson MJ, Bowie EM (2019) Assessment of intravitreal injection training among U.S.-based ophthalmology residents. J Acad Ophthalmol 11(1):e43\u2013e49. https:\/\/doi.org\/10.1055\/s-0039-1688912","journal-title":"J Acad Ophthalmol"},{"issue":"2","key":"7005_CR49","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/aos.12589","volume":"93","author":"PW Hasler","year":"2015","unstructured":"Hasler PW, Bloch SB, Villumsen J, Fuchs J, Lund-Andersen H, Larsen M (2015) Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting. Acta Ophthalmol 93(2):122\u2013125. https:\/\/doi.org\/10.1111\/aos.12589","journal-title":"Acta Ophthalmol"},{"issue":"5","key":"7005_CR50","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.1177\/11206721211060947","volume":"32","author":"I Ahmed","year":"2022","unstructured":"Ahmed I, Maghsoudlou P, Hasan H, Abumattar A, Shah N (2022) Safety and efficacy of nurse led intravitreal injection service with Precivia\u00ae injection assist device. Eur J Ophthalmol 32(5):2771\u20132776. https:\/\/doi.org\/10.1177\/11206721211060947","journal-title":"Eur J Ophthalmol"},{"issue":"1","key":"7005_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54226-7","volume":"9","author":"HE Lode","year":"2019","unstructured":"Lode HE, Gj\u00f8lberg TT, Foss S, Sivertsen MS, Brustugun J, Andersson Y, J\u00f8rstad \u00d8K, Moe MC, Andersen JT (2019) A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep 9(1):18021. https:\/\/doi.org\/10.1038\/s41598-019-54226-7","journal-title":"Sci Rep"},{"issue":"10","key":"7005_CR52","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1038\/s41433-020-01211-4","volume":"35","author":"K Gallagher","year":"2021","unstructured":"Gallagher K, Raghuram AR, Williams GS, Davies N (2021) Pre-filled aflibercept syringes-variability in expressed fluid volumes and a case series of transient central retinal artery occlusions. Eye (Lond) 35(10):2899\u20132900. https:\/\/doi.org\/10.1038\/s41433-020-01211-4","journal-title":"Eye (Lond)"},{"key":"7005_CR53","doi-asserted-by":"publisher","unstructured":"Lee DJ, Scruggs BA, S\u00e1nchez E, Thomas M, Faridi A (2022) Transient Vision Loss Associated with Prefilled\u00a0Aflibercept Syringes: A Case Series and Analysis of Injection Force. Ophthalmol Sci 2(2):100115.\u00a0https:\/\/doi.org\/10.1016\/j.xops.2022.100115","DOI":"10.1016\/j.xops.2022.100115"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-025-07005-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-025-07005-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:13:09Z","timestamp":1772791989000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-025-07005-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["7005"],"URL":"https:\/\/doi.org\/10.1007\/s00417-025-07005-2","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"21 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human or animal subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent statements"}},{"value":"G.B.M. worked as a consultant or contractor for SJJ Solutions, West Pharmaceuticals and Molecular Partners, and received\u00a0Financial Support from SJJ Solutions. The remaining authors declared no potential conflicts of interest with respect to the","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration number"}},{"value":"None to disclose.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Presentation at conferences"}}]}}